Showing results (201-210 of 258) with videos related to

Sort By:
Pageof 26
Sexually Transmitted Diseases|September 5, 2020
Unnamed Partners From Syphilis Partner Services Interviews, 7 JurisdictionsAnna Barry Cope, Kyle Bernstein, James Matthias, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersSebastian Palmqvist, Noëlle Warmenhoven, Federica Anastasi, et al.
The Journal of Prevention of Alzheimer'S Disease|June 25, 2023
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task ForceD Angioni, O Hansson, R J Bateman, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Cancer-Related FatigueV Mock, A Atkinson, A Barsevick, et al.
Annals of Clinical and Translational Neurology|August 8, 2023
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairmentMark Monane, Kim G Johnson, B Joy Snider, et al.
Molecular Neurodegeneration|May 2, 2021
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysisTim West, Kristopher M Kirmess, Matthew R Meyer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 20, 2025
Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementiaKarly A Cody, Lianlian Du, Rachel L Studer, et al.
Annals of Clinical and Translational Neurology|March 28, 2023
Independent study demonstrates amyloid probability score accurately indicates amyloid pathologyIlana Fogelman, Tim West, Joel B Braunstein, et al.
JAMA Neurology|July 28, 2024
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive ImpairmentShorena Janelidze, Nicolas R Barthélemy, Gemma Salvadó, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 17, 2024
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trialDoris Patricia Molina-Henry, Rema Raman, Andy Liu, et al.
Pageof 26